2016. Spondylarthritides Congress – Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

McInnes IB, Nash P, Mease P, Thom H, Hunger M, Gandhi K, Mpofu S, Jugl S. Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. Presented at: 10th International Congress on Spondylarthritides; September 15-17, 2016; Gent, Belgium.